BioSpace News Archive

Revenue was $41 thousand, which was generated from a software license agreement with a large post-production film company to correct defects and restore one film.

For further details on the terms of the loan, refer to the Form 8-K filed by Lipocine with the SEC on January 5, 2018.

Revenues in 2017 were $22.4 billion, an increase of 2%, or 6% in local currency terms, compared to 2016.

The approval is based on Phase 3 data from the pivotal LATITUDE clinical trial.

Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics.

Bonti announced the initiation of the SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin.

The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.

Cosentyx is currently the only fully human IL-17A antagonist to demonstrate efficacy and safety in a dedicated Phase IIIb study of scalp psoriasis.

Net sales amounted to SEK 170.1 million, an increase of 23%.

Enamine and BioSolveIT announced the launch of the ‘REAL Space Navigator’. Jointly developed, the new software tool capitalizes on Enamine’s REAL (readily accessible) virtual compound concept and provides efficient ‘search & find’ access to more than 640 million pharma-oriented molecules, to date the world’s largest chemical space of commercially accessible compounds.